Akari Therapeutics (AKTX) jumps on preclinical AKTX-101 + KRAS inhibitor synergy in pancreatic cancer; learn what it means ...
Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab ...
Akari Therapeutics (AKTX) announced on Thursday the pricing of a private placement financing round, expecting to raise an aggregate of approximately $5.5M in gross proceeds. With these funds, the ...
View Akari Therapeutics Plc Sponsored ADR AKTX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today ...
An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic ...
Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development and manufacturing company, to accelerate Akari’s drug development and ...
Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic disease Akari Therapeutics announces leadership changes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results